Gateways to Clinical Trials

Methods and Findings in Experimental and Clinical Pharmacology

Volumn 26, Issue 2, 2004, Pages 129-161

  Bayes M ^a   Rabasseda, X ^b   Prous, J R ^b  

^a PROUS SCIENCE   (Spain)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

22 OXACALCITRIOL; 5 AZA 2' DEOXYCYTIDINE; ACETYLSALICYLIC ACID; ALPHA2A INTERFERON; BOSENTAN; CALCITRIOL; CASPOFUNGIN; CLEVIDIPINE; DESLORATADINE; DEXAMETHASONE; DIPHENHYDRAMINE; DRUG; ENOXAPARIN; EPLERENONE; ERTAPENEM; FONDAPARINUX; GLYCERYL TRINITRATE; IMATINIB; IVABRADINE; MEPOLIZUMAB; NESIRITIDE; NITROPRUSSIDE SODIUM; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PANTOPRAZOLE; PEGAPTANIB; PEGINTERFERON; PIPERACILLIN PLUS TAZOBACTAM; UNINDEXED DRUG; UNIPROST; ZOFENOPRIL;

ALLERGIC RHINITIS; ANEMIA; ASPERGILLOSIS; BREAST DISEASE; CANCER; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG INDICATION; DRUG RESEARCH; GASTROESOPHAGEAL REFLUX; GENITAL SYSTEM DISEASE; HEART FAILURE; HEART INFARCTION; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPEREOSINOPHILIC SYNDROME; HYPERPARATHYROIDISM; HYPERTENSION; IMMUNOPATHOLOGY; INFECTION; INFESTATION; KIDNEY DISEASE; KIDNEY FAILURE; LEUKEMIA; MEDIASTINUM DISEASE; MENTAL DISEASE; METABOLIC DISORDER; MULTIPLE MYELOMA; NEUROLOGIC DISEASE; NUTRITIONAL DISORDER; PERITONITIS; PULMONARY HYPERTENSION; RESPIRATORY TRACT DISEASE; RETINA MACULA DEGENERATION; RETINA MACULA EDEMA; REVIEW; SICKLE CELL ANEMIA; SKIN DISEASE; THROMBOSIS; URINARY TRACT DISEASE; VOLUNTEER;

CLINICAL TRIALS AS TOPIC; HUMANS;

EID: 1842473058     PISSN: 03790355     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (229)

1. Hillery, C.A., Sillah, N.M., Wandersee, N.J. et al. Effect of fetal hemoglobin induction by decitabine on erythrocyte adhesion, coagulation parameters and markers of inflammation in patients with sickle cell disease. Blood 2002, 100 (11, Part 1): Abst 25.
2. Urosevic, M. et al. Phase I trial of repeated intralesional injection of TG1042 (adenovirus-interferon-gamma) in primary cutaneous T and B cell lymphomas. Proc Am Assoc Cancer Res 2003, 44 (2nd ed): Abst 5504.
3. Garrett, J.K., Jameson, S.C., Thomson, B. et al. Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes. J Allergy Clin Immunol 2004, 113(1): 115.
4. Hodgson, J.M. et al. Hemodynamic effects, reversibility and tolerability of a novel new adenosine A2a receptor agonist for pharmacologic stress testing. Circulation 2003, 108 (17, Suppl. 4): Abst 2889.
5. Sakamoto. T., Ogawa, H., Takazoe, K. et al. Effect of activated protein C on plasma plasminogen activator inhibitor activity in patients with acute myocardial infarction treated with alteplase: Comparison with unfractionated heparin. J Am Coll Cardiol 2003, 42(8): 1389.
6. Borghi, C. et al. Effects of zofenopril on ischemia following myocardial infarction: The SMILE study. Circulation 2003, 108 (17, Suppl. 4): Abst 3129.
7. Manz, M., Reuter, M., Lauck, G., Omran, H., Jung, W. A single intravenous dose of ivabradine, a novel If inhibitor, lowers heart rate but does not depress left ventricular function in patients with left ventricular dysfunction. Cardiology 2003, 100(3): 149.
8. Publication Committee for the VMAC Investigators (Vasodilatation in the Management of Acute CHF). Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: A randomized controlled trial. JAMA - J Am Med Assoc 2002, 287(12): 1531.
9. Bech, J.N., Bentzen, H., Nyvad, O., Thomassen, A., Pedersen, E.B. Renal and hormonal effects of NO-inhibition in patients with congestive heart failure. Nephrol Dial Transplant 2003, 18 (Suppl. 4): Abst M272.
10. Pitt, B. et al. The EPHESUS trial: Effect of eplerenone in patients with a baseline history of hypertension. Circulation 2003, 108 (17, Suppl. 4): Abst 2727.
11. Powroznyk, A.V.V., Vuylsteke, A., Naughton, C. et al. Comparison of clevidipine with sodium nitroprusside in the control of blood pressure after coronary artery surgery. Eur J Anaesthesiol 2003, 20(9): 697.
12. Turpie, A.G., Colwell, C.W., Bauer, K., Eriksson, B.I., Lassen, M.R. Fondaparinux reduces long-term risk of venous thromboembolism after surgery for hip fracture. Chest 2003, 124 (4, Suppl.): 132S.
13. Stokes, G.S., Barin, E.S., Gilfillan, K.L., Kaesemeyer, W.H. Interactions of L-arginine, isosorbide mononitrate, and angiotensin II inhibitors on arterial pulse wave. Am J Hypertens 2003, 16(9): 719.
14. Ruiz, M.J. et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin stable analogue, in primary pulmonary hypertension: 3 year experience. Eur Heart J 2003. 24 (Suppl.): Abst P3384.
15. Sitbon, O. et al. Haemodynamic and clinical improvement with bosentan in patients with pulmonary arterial hypertension associated with HIV infection. Eur Heart J 2003, 24 (Suppl.): Abst 2568.
16. Hull, R.D., Burke, N., Mah, A.F., Pineo, G.F. Timing of initial administration of prophylaxis against deep vein thrombosis in patients following hip of knee surgery. Chest 2003, 124 (4, Suppl.): 240S.
17. Eriksson, H., Wahlander, K., Gustafsson, D., Welin, L.T., Frison, L., Schulman, S. A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I. J Thromb Haemost 2003, 1(1): 41.
18. Gordon, S. et al. Parecoxib sodium 40 mg IM is as effective as morphine 12 mg IM following gynecologic laparotomy. 4th Congr Eur Fed IASP Chapters (Sept 2, 2003, Prague) 2003: Abst 611.T.
19. Tanaka, M., Itoh, K., Matsushita, K. et al. The usefulness of the combination therapy with intravenous maxacalcitol therapy and percutaneous ethanol injection therapy (PEIT) in secondary hyperparathyroidism. Nephrol Dial Transplant 2003, 18 (Suppl. 4): Abst M462.
20. Ishimura, E., Okuno, S., Kitatani, K. et al. Relationship between parathyroid gland size and responsiveness to maxacalcitol therapy in patients with secondary hyperparathyroidism. Nephrol Dial Transplant 2003, 18 (Suppl. 4): Abst M459.
21. Dupre, J., Behme, M.T., McDonald, T.J. Exendin-4 reduces glycemic excursions after meals in insulin-treated diabetes. Diabetes 2002, 51 (Suppl. 2): Abst 342-OR.
22. Stewart, W.C. Prevention of corticosteroid-induced intraocular pressure elevation using ISV-205. Arch Ophthalmol 2003, 121(11): 1543.
23. Fish, G., Haller, J.A., Ho, A.C. et al. Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: Phase II study results. Ophthalmology 2003, 110(5): 979.
24. Regillo, C.D. et al. Safety results of two phase 3 trials of SnET2 photodynamic therapy for age-related macular degeneration. Annu Meet Am Acad Ophthalmol (Nov 15, 2003, Anaheim) 2003: Abst PO287.
25. Thomas, E.L. et al. Efficacy results of two phase 3 trials of SnET2 photodynamic therapy for age-related macular degeneration. Annu Meet Am Acad Ophthalmol (Nov 15. 2003, Anaheim) 2003: Abst PA062.
26. Simon, B., Müller, P., Pascu, O. et al. Intra-oesophageal pH profiles and pharmacokinetics of pantoprazole and esomeprazole: A crossover study in patients with gastro-oesophageal reflux disease. Eur J Gastroenterol Hepatol 2003, 15(7): 791.
27. Teppler, H., Meibohm, A., Woods, G., Gesser, R. Ertapenem once a day is highly effective for treatment of generalized peritonitis. Clin Microbiol Infect 2003, 9 (Suppl. 1): Abst P781.
28. Shinohara, M., Ishii, K., Takamura, N. et al. Effect of consensus IFN and ribavirin in combination with IFN on host factors in patients with chronic hepatitis C. 53rd Annu Meet Am Assoc Study Liver Dis (Nov 1, 2002, Boston) 2002: Abst 1749.
29. Neau, D., Trimoulet, P., Winnock, M. et al. Efficacy and tolerance of interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-infected patients. 42nd Intersci Conf Antimicrob Agents Chemother (Sept 27, 2002, San Diego) 2002: Abst V-683.
30. Quereda, C., Moreno, L., Moreno, A. et al. Early prediction of response to pegylated Interferon-alfa 2b plus ribavirine (RBV) in patients coinfected with HIV and HCV. 42nd Intersci Conf Antimicrob Agents Chemother (Sept 27, 2002, San Diego) 2002: Abst H-1724.
31. Wilken, J.A. et al. A comparison of the effect of diphenhydramine and desloratadine on vigilance and cognitive function during treatment of rag weed-induced allergic rhinitis. Ann Allergy Asthma Immunol 2003, 91(4): 375.
32. Bachert, C., Bousquet, J., Canonica, G.W. et al. XPERT: Levocetirizine long term treatment in patients suffering from persistent allergic rhinitis. 22nd Congr Eur Acad Allergol Clin Immunol (June 7, 2003, Paris) 2003: Abst 239.
33. Dadhich, P., Vats, M., Lokendra, D., Gupta, R.C., Gupta, M.L., Gupta, N. Magnesium sulphate nebulization in acute severe asthma. Chest 2003, 124 (4, Suppl.): 107S.
34. Ullmann, A.J., Van Burik, J.A., McSweeney, P. et al. An open phase II study of the efficacy of micafungin (FK463) alone and in combination for the treatment of invasive aspergillosis (IA) in adults and children. Clin Microbiol Infect 2003, 9 (Suppl. 1): Abst 0400.
35. DiNubile, M., Sable, C., Kartsonis, N. Safety and tolerability of caspofungin therapy for elderly patients with invasive candidiasis or invasive aspergillosis. Clin Microbiol Infect 2003, 9 (Suppl. 1): Abst P546.
36. Zervos, M., Aubier, M., Nusrat, R. Telithromycin is highly efficacious in the treatment of lower respiratory tract infections. Eur Respir J 2003, 22 (Suppl. 45): Abst P986.
37. Jones, L.A., Woolan, J.B., Johnson, L.D., Kylstra, J., Laus, R., Park, J.W. Detecting immune responses to Her-2/neu in breast cancer patients following treatment with APC8024, a therapeutic vaccine. Proc Am Assoc Cancer Res 2003, 44 (2nd ed): Abst 3844.
38. Kuppermann, B.D., Haller, J.A., Williams, G.A., Blumenkranz, M.S. A randomized controlled trial to assess the safety and efficacy of a dexamethasone implant for diabetic macular edema. Annu Meet Am Acad Ophthalmol (Nov 15, 2003, Anaheim) 2003: Abst PA092.
39. Tagliaferri, A., Rossetti, G., Franchini, M. et al. Interferon plus ribavirin in hemophiliacs with chronic hepatitis C nonresponder to interferon monotherapy. Blood 2002, 100 (11, Part 1): Abst 2796.
40. Morris, A.K., Gibb, A.P., Morgan, R., Philip, C., Sloan, F. Audit of linezolid use within a large teaching NHS Trust. Clin Microbiol Infect 2003, 9 (Suppl. 1): Abst P1025.
41. Nathwani, D., Gray, K. Clinical experience of linezolid in a UK teaching hospital. Clin Microbiol Infect 2003, 9 (Suppl. 1): Abst P482.
42. Chrysos, G., Anagnostopoulou, S., Kakatsos, J. et al. Clinical experience with linezolid in Greek patients with Gram-positive infections. Clin Microbiol Infect 2003, 9 (Suppl. 1): Abst P796.
43. Carbon, C., Roos, K., Rangaraju, M., Nusrat, R. Telithromycin is highly effective against macrolide-resistant Streptococcus pneumoniae: A pooled analysis of 11 multicenter clinical trials. Clin Microbiol Infect 2003, 9 (Suppl. 1): Abst P1127.
44. Friedland, I., Isaacs, R., Moll, J., Adeyi, B., Woods, G. Healthcare associated pneumonia acquired outside the ICU: Results of a randomized, double-blind study comparing ertapenem and cefepime. Clin Microbiol Infect 2003, 9 (Suppl. 1): Abst P788.
45. Woods, G., Isaacs, R., McCarroll, K., Friedland, I. Ertapenem for treatment of CAP caused by Gram-negative enteric pathogens. Clin Microbiol Infect 2003, 9 (Suppl. 1): Abst P782.
46. Carmeli, Y., Schwaber, M., Weber, S., Bolon, M. Vancomycin to linezolid switch in patients with MRSA infection. Clin Microbiol Infect 2003, 9 (Suppl. 1): Abst P798.
47. Wunderink, R.G. et al. Linezolid vs vancomycin: Analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 2003, 124(5): 1789.
48. Dunbar, L.M., Carbon, C., Nusrat, R. Telithromycin displays high clinical efficacy in outpatients with mild to moderate community-acquired pneumonia caused by atypical/intracellular pathogens. Eur Respir J 2003, 22 (Suppl. 45): Abst P984.
49. Woods, G., Isaacs, R., McCarroll, K., Friedland, I. Serious community-acquired pneumonia in patients with chronic obstructive pulmonary disease: Utility of ertapenem. Clin Microbiol Infect 2003, 9 (Suppl. 1): Abst P785.
50. Diamantea, F., Koratzanis, G., Katsargiris, J. et al. Efficacy and safety of telithromycin in two treatments of acute sinusitis in adults. Clin Microbiol Infect 2003, 9 (Suppl. 1): Abst P806.
51. Postema, E.J., Borjesson, P.K.E., Buijs, W.C.A.M. et al. Dosimetric analysis of radioimmunotherapy with 186Re-labeled bivatuzumab in patients with head and neck cancer. J Nucl Med 2003, 44(10): 1690.
52. Scott, A.M. et al. A phase I dose-escalation study of sibrotuzumab in patients with advanced of metastatic fibroblast activation protein-positive cancer. Clin Cancer Res 2003, 9(5): 1639.
53. Weyer, C., Fineman, M., Burrell, T., Strobel, S., Shen, L., Kolterman, O. Adjunctive therapy with pramlintide lowers Alc without concomitant weight gain in patients with type 2 diabetes approaching ADA glycemic targets. Diabetes 2003, 52 (Suppl. 1): Abst 591-P.
54. Hathout, E., Geach, J., Fujishige, L., Ischandar, M., Maruo, S., Mace, J. Effect of therapy with insulin glargine on glycemic control in toddlers, children, and adolescents with diabetes. Diabetes 2003, 52 (Suppl. 1): Abst 1738-P.
55. Weyer, C., Kim, D., Burrell, T. et al. Mealtime amylin replacement with pramlintide markedly reduced postprandial glucose excursions when added to insulin lispro in patients with type 1 or type 2 diabetes. Diabetes 2003, 52 (Suppl. 1): Abst 70-OR.
56. Dupre, J., Behme, M.T., McDonald, T.J. Exendin-4 reduces glycemic excursions after meals in C-peptide-negative type 1 diabetes more effectively than glucagon-like peptide 1. 18th Int Diabetes Fed Congr (Aug 24, 2003, Paris) 2003: Abst 1771.
57. Behme, M., Dupre, J., McDonald, T. Exendin-4 normalizes glycemic excursions in C-peptide-negative type 1 diabetes. Diabetes 2003, 52 (Suppl. 1): Abst 472-P.
58. Bott, S., Tusek, C., Jacobsen, L., Kristensen, A., Heise, T. Insulin detemir reaches steady-state after the first day of treatment and shows a peakless time-action profile with twice daily-applications. Diabetes 2003, 52 (Suppl. 1): Abst 480-P.
59. Ashwell, S., Amiel, S., Bilous, R., Heller, S., Hepburn, D., Home, P. Improvement in HbA1c with insulin glargine+insulin lispro in comparison with NPH insulin+unmodified human insulin in people with type 1 diabetes. Diabetes 2003, 52 (Suppl. 1): Abst 1914-PO.
60. Murphy, N.P. et al. Randomized cross-over trial of insulin glargine plus lispro or NPH insulin plus regular human insulin in adolescents with type 1 diabetes on intensive insulin regimens. Diabetes Care 2003, 26(3): 799.
61. Dixon, B., Chase, H.P., Fiallo-Scharer, R. et al. The addition of insulin glargine to lower hypoglycemic events and AIC levels in children and adolescents with type 1 diabetes. Diabetes 2003, 52 (Suppl. 1): Abst 1736-P.
62. Schreiber, S., Rubmann, A. Evaluation of the long-term efficacy of insulin glargine (Lantus) in patients with type 1 diabetes in clinical practice. Diabetes 2003, 52 (Suppl. 1): Abst 1973-PO.
63. Torlone, E., Pampanelli, S., Porcellati, F. et al. Short-term comparison between glargine as basal insulin and CS11 in CS11-treated type I diabetic patients switching to MD1: The pump holiday study. Diabetes 2003, 52 (Suppl. 1): Abst 13-LB.
64. Kolterman, O., Burrell, T., Shen, L. et al. Initiation of pramlintide using dose-titration in intensively-treated patients with type I diabetes resulted in mitigation of nausea and hypoglycemia. Diabetes 2003, 52 (Suppl. 1): Abst 62-LB.
65. Hermansen, K., Colombo, M., Storgaard, H., Ostergaard, A., Kolendorf, K., Madsbad, S. Improved postprandial glycemic control with biphasic insulin aspart relative to biphasic insulin lispro and biphasic human insulin in patients with type 2 diabetes. Diabetes Care 2002, 25(5): 883.
66. McSorley, P.T., Bell, P.M., Jacobsen, L.V., Kristensen, A., Lindholm, A. Twice-daily biphasic insulin aspart 30 versus biphasic human insulin 30: A double-blind crossover study in adults with type 2 diabetes mellitus. Clin Ther 2002, 24(4): 530.
67. Neil, A., Wheeler, F., Cull, C., Manley, S., Keenan, J., Holman, R. Combination statin and fibrate therapy in type 2 diabetes: Results from the Lipids in Diabetes Study. Diabetes 2003, 52 (Suppl. 1): Abst 317-OR.
68. Kim, D., Taylor, K., Bicsak, T. et al. Subcutaneous injection of AC2993 (synthetic exendin-4) lowered fasting glucose concentrations through suppression of glucagon and dose dependent insulinotropism in patients with type 2 diabetes. Diabetes 2002, 51 (Suppl. 2): Abst 421-P.
69. Fineman, M.S., Bicsak, T., Shen, L. et al. AC2993 (synthetic exendin-4) added to existing metformin (Met) and/or sulfonylurea (SFU) treatment improved glycemic control in patients with type 2 diabetes (DM2) during 28 days of treatment. Diabetes 2002, 51 (Suppl. 2): Abst 343-OR.
70. Baron, A., Poon, T., Taylor, K. et al. Exenatide (synthetic exendin-4) showed marked HbAlc decline over 5 months in patients with type 2 diabetes failing oral agents in an open-label study. Diabetes 2003, 52 (Suppl. 1): Abst 3-LB.
71. Schreiber, S., Rubmann, A. Long-term administration of insulin glargine (Lantus): Metabolic and weight benefits in patients with type 2 diabetes in clinical practice. Diabetes 2003, 52 (Suppl. 1): Abst 1972-PO.
72. Matto, V., Malone, J., Tiku, A. et al. Humalog MIX25 (25%NPL:75%lispro) is a safe and effective alternative to human insulin 30/70 (30%R:70%NPH) in the treatment of type 2 elderly diabetes. Diabetes 2003, 52 (Suppl. 1): Abst 1958-PO.
73. Davidson, J., Perez, A., Popovici, C., Zhang, J. Addition of pioglitazone to stable insulin therapy in poorly controlled patients with type 2 diabetes: Results of a double-blind, multicenter, randomized study. Diabetes 2003, 52 (Suppl. 1): Abst 1927-PO.
74. Poulsen, M.K., Henriksen, J.E., Hother-Nielsen, O., Beck-Nielsen, H. The combined effect of triple therapy with rosiglitazone, metformin, and insulin aspart in type 2 diabetic patients. Diabetes Care 2003, 26(12): 3273.
75. Marbury, T., Schwartz, S., Rosenberg, M. et al. Evaluation of the safety, efficacy and tolerability of insulin glargine in subjects with impaired fasting glucose, impaired glucose tolerance or new-onset type 2 diabetes. Diabetes 2003, 52 (Suppl. 1): Abst 1955-PO.
76. Boehm, B., Home, P., Rastam, J., Keiding, J. Safety and efficacy of long term exposure to biphasic insulin aspart compared with biphasic human insulin in people with type 2 diabetes. 18th Int Diabetes Fed Congr (Aug 24, 2003, Paris) 2003: Abst 778.
77. Isaacs, R., Gesser, R., Teppler, H., Friedland, I., McCarroll, K., Woods, G. Etrapenem 1g once a day is highly effective for treatment of community-acquired and mixed infections in adults with diabetes. Clin Microbiol Infect 2003, 9 (Suppl. 1): Abst O139.
78. Fischer, J., Roberts, C., McLaughlin, T. et al. Twelve-month effectiveness of insulin glargine use in diabetic patients from an endocrinology speciality practice. Diabetes 2003, 52 (Suppl. 1): Abst 1933-PO.
79. Ströberg, P. et al. Switching patients with erectile dysfunction from sildenafil citrate to tadalafil: Results of a European multicenter, open-label study of patient preference. Clin Ther 2003, 25(11): 2724.
80. Stein, E.A., Strutt, K., Southworth, H., Diggle, P.J., Miller, E. Comparison of rosuvastatin versus atorvastatin in patients with heterozygous familial hypercholesterolemia. Am J Cardiol 2003, 92(11): 1287.
81. Simons, L., Masana, L., Tonkon, M., Shah, A., Maccubbin, D., Gumbiner, B. Effects of ezetimibe added to on-going statin therapy on LDL-C goal attainment in high risk hypercholesterolemic patients with or without type 2 diabetes mellitus. 18th Int Diabetes Fed Congr (Aug 24, 2003, Paris) 2003: Abst 1028.
82. Sager, P, et al. C-Reactive protein is reduced during ezetimibe coadministration with simvastatin in patients with primary hypercholesterolaemia. Eur Heart J 2003, 24 (Suppl,): Abst 3553.
83. Detke, M., Goldstein, D., Lu, Y., Iyengar, S., Lee, T. Efficacy of duloxetine in the treatment of the pain associated with diabetic neuropathy. 18th Int Diabetes Fed Congr (Aug 24, 2003, Paris) 2003: Abst 912.
84. Hukshorn, C.J. et al. Pegylated human recombinant leptin (PEG-OB) causes additional weight loss in severely energy-restricted, overweight men. Am J Clin Nutr 2003, 77 (4):771.
85. Lteif, A., Steinberg, H., Mather, K. Endothelin antagonism, but not vasodilation per se, improves endothelial function in obesity. Diabetes 2003, 52 (Suppl. 1): Abst 2061-PO.
86. Miller, D.S., Blessing, J., Waggoner, S., Schilder. J., Sorosky, J., Bloss, J. Phase II evaluation of aminocamptothecin (9-AC, NSC #603071) in recurrent, platinum-resistant and refractory ovarian and primary peritoneal carcinoma: A Gynecologic Oncology Group Study (G.O.G.). Proc Am Soc Clin Oncol 2003, 22: Abst 1854.
87. Armstrong, D.K., Blessing, J.A., Look, K.Y., Schilder, R., Nunez, E.R. A randomized phase II evaluation of bryostatin-1 (NSC #339555) in recurrent or persistent platinum-sensitive ovarian cancer: A Gynecologic Oncology Group Study. Invest New Drugs 2003, 21(3): 373.
88. Levine, A.M., Fayad, L., Tulpule, A. et al. Results of a phase I/II trial with BBR-2778 (Pixantrone), methylprednisolone, cisplatin, and cytosine arabinoside (BSHAP) in relapsed/refractory aggressive non-Hodgkin's lymphoma (NHL). Blood 2003, 102 (11, Part 1): Abst 2364.
89. Smaletz, O., Galsky, M., Scher, H.I. et al. Pilot study of epothilone B analog (BMS-247550) and estramustine phosphate in patients with progressive metastatic prostate cancer following castration. Ann Oncol 2003, 14(10): 1518.
90. Piekarz, R., Robey, R., Fojo, T. et al. Analysis of molecular markers and targets in trials of depsipeptide, FR901228, a histone deacetylase inhibitor with clinical activity in T-cell lymphoma. Proc Am Soc Clin Oncol 2002, 21 (Part 2): Abst 88.
91. Garrison, M.A., Hammond, L.A., Geyer, C.E. Jr. et al. A phase I and pharmocokinetic study of exatecan mesylate administered as a protracted 21-day infusion in patients with advanced solid malignancies. Clin Cancer Res 2003, 9(7): 2527.
92. Esteva, F.J., Rivera, E., Cristofanilli, M. et al. A phase II study of intravenous exatecan mesylate (DX-895If) administered daily for 5 days every 3 weeks to patients with metastatic breast carcinoma. Cancer 2003, 98(5): 900.
93. Mauro, M.J., Druker, B.J., Kuyl, J., Kurilik, G., Maziarz, R.T. Increasing levels of detectable leukemia in imatinib treated CML patients with previously undetectable or very low levels of Bcr-Abl. Proc Am Soc Clin Oncol 2003, 22: Abst 2288.
94. Lara, P.N., Frankel, P., Mack, P.C. et al. Tirapazamine plus carboplatin and paclitaxel in advanced malignant solid tumors: A California Cancer Consortium phase I and molecular correlative study. Clin Cancer Res 2003, 9(12): 4356.
95. Liu, G., Oettel, K., Bailey, H. et al. Phase II trial of perillyl alcohol (NSC 641066) administered daily in patients with metastatic androgen independent prostate cancer. Invest New Drugs 2003, 21(3): 367.
96. Rosen, L.S., Gordon, D., Belch, A., Seaman, J., Chen, B.-L. Long-term (25-month) efficacy and safety of 4 mg zoledronic acid for the treatment of multiple myeloma bone disease: A randomized, phase III, comparative trial with pamidronate. Blood 2002, 100 (11, Part 2): Abst 5139.
97. Coiffier, B. et al. Efficacy and safety of rasburicase (recombinant tirate oxidase) for the prevention and treatment of hyperuricemia urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: Results of the GRAALI (Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma) study. J Clin Oncol 2003, 21(23): 4402.
98. Gomez, H., Hanauske, A.-R., Santillana, S. et al. A phase II trial of pemetrexed in previously untreated breast cancer. Breast Cancer Res Treat 2002, 76 (Suppl. 1): Abst 226.
99. O'Farrell, A.M., Foran, J.M., Fiedler, W. et al. An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. Clin Cancer Res 2003, 9(15): 5465.
100. Crombet-Ramos, T., Osorio, M., Cruz, T. et al. Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. 2nd Int Symp Signal Transduct Modul Cancer Ther (Oct 23, 2003, Amsterdam) 2003: Abst C.03.
101. Harousseau, J.-L., Reiffers, J., Lowenberg, B. et al. Zarnestra™ (R115777) in patients with relapsed and refractory acute myelogenous leukemia (AML): Results of a multicenter phase 2 study. Blood 2003, 102 (11, Part 1): Abst 614.
102. Hussain, M.M., Kotz, H., Minasian, L. et al. Phase II trial of carboxyamidotriazole in patients with relapsed epithelial ovarian cancer. J Clin Oncol 2003, 21(23): 4356.
103. Estey, E.H., Fisher, T., Giles, F. et al. A randomized phase II trial of the tyrosine kinase inhibitor PKC412 in patients (pts) with acute myeloid leukemia (AML)/high-risk myelodysplastic syndromes (MDS) characterized by wild-type (WT) or mutated FLT3. Blood 2003, 102 (11, Part 1): Abst 2270.
104. Borchmann, P., Schnell, R., Morschhauser, F. et al. A phase I study of pixantrone (BBR 2778) in combination with cyclophosphamide, vincristine and prednisone in patients with relapsed aggressive non-Hodgkin's lymphoma. Blood 2003, 102 (11, Part 1): Abst 2369.
105. Morgan-Meadows, S., Dubey, S., Gould, M. et al. Phase I trial of perillyl alcohol administered four times daily continuously. Cancer Chemother Pharmacol 2003, 52(5): 361.
106. Raza, A., Bonamici, S., Nucifora, G. et al. Thalidomide and arsenic trioxide for the treatment of myelodysplastic syndromes (MDS). Proc Am Soc Clin Oncol 2003, 22: Abst 2356.
107. Simoes, B.P., Stanglmaier, M., Faltin, M. et al. Bi20 a new trifunctional bispecific antibody (CD20xCD3) in the treatment of resistant B cell tumors: First clinical data. Blood 2003, 102 (11, Part 2): Abst 4910.
108. Braybrooke, J.P., Boven, E., Bates, N.P. et al. Phase I and pharmacokinetic study of the topoisomerase I inhibitor, exatecan mesylate (DX-895If), using a weekly 30-minute intravenous infusion, in patients with advanced solid malignancies. Ann Oncol 2003, 14(6): 913.
109. Ratain, M.J., O'Dwyer, P., Stadler, W. et al. A phase II study of BAY 43-9006 using the randomized discontinuation desing in patients with advanced refractory cancer. 2nd Int Symp Signal Transduct Modul Cancer Ther (Oct 23, 2003, Amsterdam) 2003: Abst O.24.
110. O'Reilly, E.M., Lenzi, R., Mani, S. et al. Final results of a phase I study of DX-895If (DX) and gemcitabine (Gem) in advanced solid tumor. Proc Am Soc Clin Oncol 2002, 21 (Part 1): Abst 394.
111. Guo, X.D. et al. Pharmacokinetic and pharmacodynamic effects of oral eniluracil, fluorouracil and leucovorin given on a weekly schedule. Cancer Chemother Pharmacol 2003, 52(1): 79.
112. Cappuzzo, F. et al. Epidermal growth factor receptor targeted therapy by ZD 1839 (Iressa) in patients with brain metastases from non-small cell lung cancer (NSCLC). Lung Cancer (Ireland) 2003, 41(2): 227.
113. Jayson, G.C., Parker, G., Mullamitha, S. et al. Is it desirable to inhibit PDGFR-β? 2nd Int Symp Signal Transduct Modul Cancer Ther (Oct 23, 2003, Amsterdam) 2003: Abst O.07.
114. Verschraegen, C.F. et al. A phase II study of intravenous exatecan mesylate (DX-895If) administered daily for 5 days every 3 weeks to patients with advanced ovarian, tubal or peritoneal cancer resistant to platinum, taxane and topotecan. Cancer Chemother Pharmacol 2004, 53(1): 1.
115. Drucker, B., Bacik, J., Ginsburg, M. et al. Phase II trial of ZD1839 (Iressa™) in patients with advanced renal cell carcinoma. Invest New Drugs 2003, 21(3): 341.
116. Fraunfelder, F.W. et al. Ocular side-effects associated with imatinib mesylate (Gleevec®). J Ocular Pharmacol Ther 2003, 19(4): 371.
117. O'Shaughnessey, J., Liepa, A.M., Nguyen, B. Symptom improvement with pemetrexed for heavily pretreated patients with advanced breast cancer. Breast Cancer Res Treat 2002, 76 (Suppl. 1): Abst 530.
118. Joseph, D., Chern, B., Pittman, K. et al. An assessment of patient preferences for intravenous zoledronic acid or pamidronate in patients commencing bisphosphonate therapy for malignant disease in bone. Blood 2002, 100 (11, Part 2): Abst 5114.
119. Dittrich, C., Dieras, V., Kerbrat, P. et al. Phase II study of XR5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with advanced ovarian cancer. Invest New Drugs 2003, 21(3): 347.
120. Crombet-Ramos, T., Neninger, E., Catala, M. et al. Epidermal growth factor based cancer vaccine for non-small cell lung cancer therapy: 5 years of experience. 2nd Int Symp Signal Transduct Modul Cancer Ther (Oct 23, 2003, Amsterdam) 2003: Abst O.17.
121. Mautner, V., palmer, D.H., Bonney, S, et al. Virus-directed enxyme prodrug therapy for cancer: Clinical trials with an adenovirus encoding bacterial nitroreductase (Ad-ntr). 11th Annu Congr Eur Soc Gene Ther (Nov 14, 2003. Edinburgh) 2003: Abst Or 25.
122. Witzig, T.E., Geyer, S.M., Salim, M. et al. A phase II trial of the rapamycin analog CCI-779 in previously treated mantle cell non-Hodgkin's lymphoma: Interim analysis of 18 patients. Blood 2003, 102 (11, Part I): Abst 2374.
123. Madhusudan, S., Protheroe, A., Propper, D. et al. A multicentre phase II trial of bryostatin-I in patients with advanced renal cancer. Br J Cancer 2003, 89(8): 1418.
124. Castro, J.E., Cantwell, M.J., Prussak, C.E., Bole, J., Wierda, W.G., Kipps, T.J. Long-term follow up of chronic lymphocytic leukemia patients treated with CD40-ligand (CD154) gene therapy. Blood 2003, 102 (11, Part 1): Abst 1790.
125. Slavc, I., Schuller, E., Falger, J. et al. Feasibility of long-term intraventricular therapy with mafosfamide (N=26) and etoposide (N=11): Experience in 26 children with disseminated malignant brain tumors. J Neuro-Oncol 2003, 64(3): 239.
126. Borchmann, P., Enfert, A., Davite, C., Camboni, G. Evaluation of cardiac events in patients treated with pixantrone, a novel anthracycline derived drug. Blood 2003, 102 (11, Part 2): Abst 4887.
127. Fruehauf, S., Topaly, J., Buss, E.C. et al. Interim results of a multicenter study to determine the efficacy and safety of the combination of imatinib mesylate with mitoxantrone/etoposide and cytarabine in patients with chronic myeloid leukemia in myeloid blast crisis. Proc Am Soc Clin Oncol 2003, 22: Abst 2369.
128. Gotlib, J., Loh, M., Lancet, J.E. et al. Phase I/II study of tipifarnib (Zarnestra™, farnesyltransferase inhibitor [FTI] RII5777) in patients with myeloproliferative disorders (MPDs): Interim results. Blood 2003, 102 (11, Part 1): Abst 3425.
129. Mehta, M.P., Rodrigus, P., Terhaard, C.H.J. et al. Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. J Clin Oncol 2003, 21(13): 2529.
130. Armand, J.P., Raymond, E., Faivre, S. et al. Preclinical and early clinical experience with SU11248, a novel oral multi-targeted receptor tyrosine kinase inhibitor. 2nd Int Symp Signal Transduct Modul Cancer Ther (Oct 23, 2003, Amsterdam) 2003: Abst O.10.
131. Lancet, J.E., Gojo, I., Gotlib, J. et al. Tipifarnib (Zarnestra) in previously untreated poor-risk AML and MDS: Interim results of a phase 2 trial. Blood 2003, 102 (11, Part 1): Abst 613.
132. Gralla, R., Lichinitser, M., Vander Vegt, S. et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: Results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 2003, 14(10): 1570.
133. Ferrajoli, A., Thomas, D.A., Albitar, M. et al. Alemtuzumab for minimal residual disease in CLL. Proc Am Soc Clin Oncol 2003, 22: Abst 2290.
134. Saville, W., Kipps, T.J., Cantwell, M.J. et al. A phase II trial of immune therapy for chronic lymphocytic leukemia. Blood 2003, 102 (11, Part 1): Abst 1592.
135. Smith, S.M., Stock, W. Sher, D. et al. Engraftment and early treatment-related complications after fludarabine-melphalan-Campath conditioning in patients with advanced hematologic malignancies. Blood 2002, 100 (11, Part 2): Abst 5292.
136. DiNubile, M., Hille, D., Sable, C., Kartsonis, N. Caspofungin treatment of invasive candidiasis in cancer patients. Clin Microbiol Infect 2003, 9 (Suppl. 1): Abst O396.
137. Langevin, A.M. et al. Phase I trial of rebeccamycin analog (NSC #655649) in children with refractory solid tumors: A pediatric oncology group study. J Pediatr Hematol Oncol 2003, 25(7): 526.
138. Gotlib, J., Mauro, M., O'Dwyer, M.E. et al. Tipifarnib (Zarnestra™) and imatinib (Gleevec™) combination therapy in patients with advanced chronic myelogenous leukemia (CML): Preliminary results of a phase I study. Blood 2003, 102 (11, Part 1): Abst 3384.
139. Wolff, A.C., Donehower, R.C., Carducci, M.K. et al. Phase I study of docosahexaenoic acid-paclitaxel: A taxane-fatty acid conjugate with a unique pharmacology and toxicity profile. Clin Cancer Res 2003, 9(10): 3589.
140. Davies, A.J., Rohatiner, A.Z.S., Howell, S. et al. Durable remissions and minor late toxicity may be obtained in patients treated at first or second recurrence of B cell non-Hodgkin's lymphoma (NHL) with tositumomab and I 131 tositumomab. Proc Am Soc Clin Oncol 2003, 22: Abst 2405.
141. Lipton, J.H., Khoroshko, N.D., Golenkov, A.K. et al. A randomized multicenter comparative study of peginterferon alfa-2a (40KD) vs interferon-alfa-2a in patients with treatment-naïve chronic myelogenous leukemia. Blood 2002, 100 (11, Part 1): Abst 3091.
142. Saba, H.I., Morelli, G.A., Tannenbaum, B., Loughran, T.P. Single-center experience of Campath (alemtuzumab) treatment of refractory chronic lymphocytic leukemia (CLL) patients. Blood 2002, 100 (11, Part 2): Abst 5017.
143. Wang, Y., Yap, A., Schran, H., Cohen, P. Pharmacokinetics and pharmacodynamics of PKC412, a FLT3 receptor inhibitor, following oral doses in
144. De Jonge, M.J.A., Punt, C.J.A., Sparreboom, A. et al. Phase I and pharmacologic study of oral ZD9331, a novel nonpolyglutamated thymidylate synthase inhibitor, in adult patients with solid tumors. J Clin Oncol 2002, 20(7): 1923.
145. Verschraegen, C.F., Kumagai, S., Davidson, R. et al. Phase I clinical and pharmacological study of intraperitoneal cis-bis-neodecanoato(trans-R,R-I,2-diaminocyclohexane)-platinum II entrapped in multilamellar liposome vesicles. J Cancer Res Clin Oncol 2003, 129(10): 549.
146. Twelves, C., Reck, M., Anthoney, A., Gatzemeier, U., Kaye, S. A phase I study of ZD0473 combined with paclitaxel for the treatment of solid malignancies. Cancer Chemother Pharmacol 2003, 52(4): 277.
147. Hahn, E.A., Glendenning, G.A., Sorensen, M.V. et al. Quality of life in newly diagnosed chronic phase chronic myeloid leukemia: IRIS study results of interferon-α plus Ara-C vs imatinib. Proc Am Soc Clin Oncol 2003, 22: Abst 2367.
148. Kudelka, A., Skubitz, K., Kavanach, J., Garzone, P.G., Bolton, M.G. Phase I study of Xyotax (CT-2I03) and cisplatin in patients with solid tumors: Preliminary data. Eur J Cancer 2002, 38 (Suppl. 7): Abst 436.
149. Smit, F., Douillard, J.-Y., Kris, M. et al. Gefitinib ('Iressa", ZDI839) improves disease-related symptoms in NSCLC. Eur Respir J 2003, 22 (Suppl. 45): Abst P311.
150. Cobleigh, M.A., Langmuir, V.K., Sledge, G.W. et al. A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 2003, 30 (5, Suppl. 16):117.
151. Berenson, J., Yang, H., Vescio, R., Swift, R., Sadler, K. Preliminary findings in a phase I/II study of Trisenox (arsenic trioxide) dosed twice weekly in patients with advanced multiple myeloma. Blood 2002, 100 (11, Part 2): Abst 5140.
152. Wadleigh, M. et al. Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood 2003, 102(5): 1578.
153. Montorsi, F., McCullough, A., Brock, G. et al. Tadalafil in the treatment of erectile dysfunction following bilateral nerve-sparing radical retropubic prostatectomy. Int J Impot Res 2003, 15 (Suppl. 5): Abst 21.
154. DeLoughery, T.G., Middleton, V.W., O'Dwyer, M.E. Preliminary results of a phase II trial of imatinib mesylate 600 mg in agnogenic myeloid metaplasia. Blood 2002, 100 (11, Part 2): Abst 4944.
155. Feldman, E.J., Cortes, J., Holyoake, T.L. et al. Continuous oral lonafarnib (Sarasar™) for the treatment of patients with myelodysplastic syndrome. Blood 2003, 102 (11, Part 1): Abst 1531.
156. Mesa, R.A., Camoriano, J.K., Geyer, S.M. et al. A phase 2 consortium (P2C) trial of R115777 (Zarnestra) in myelofibrosis with myeloid metaplasia: Interim analysis of 18 patients. Blood 2003, 102 (11, Part 1): Abst 3428.
157. Borad, M., Vescio, R., Yang, H.H., Swift, R., Berenson, J.R. Melphalan, arsenic trioxide (ATO) and ascorbic acid combination therapy (MAC) for treatment of refractory multiple myeloma (MM). Proc Am Soc Clin Oncol 2003, 22: Abst 2427.
158. Streetly, M., Macey, M.G., McCarthy, D.A. et al. Changes in neutrophil phenotype following the administration of CC-4047 (Actimid) to patients with multiple myeloma. Blood 2003, 102 (11, Part 1): Abst 2543.
159. Richardson, P.G., Jagannath, S., Schlossman, R. et al. A multi-center, randomized, phase 2 study to evaluate the efficacy and safety of 2 CDC-5013 dose regimens when used alone or in combination with dexamethasone (Dex) for the treatment of relapsed or refractory multiple myeloma (MM). Blood 2003, 102 (11, Part 1): Abst 825.
160. Patten, P.E., Ahsan, G., Kazmi, M. et al. The early use of the serum free light chain assay in patients with relapsed refractory myeloma receiving treatment with a thalidomide analogue (CC-4047). Blood 2003, 102 (11, Part 1): Abst 1640.
161. List, A.F., Kurtin, S., Glinsman-Gibson, B. et al. Efficacy and safety, of CC5013 for treatment of anemia in patients with myelodysplastic syndromes (MDS). Blood 2003, 102 (11, Part 1): Abst 641.
162. Bahlis, N.J., Liu, L., Cooper, B., Laughlin, M, O'Brien, T., Gerson, S. Phase II study of O6-benzylguanine (O6-BG) and BCNU in Multiple Myeloma. Proc Am Soc Clin Oncol 2003, 22: Abst 2420.
163. Steerly, M., Jones, R.W., Knight, R. et al. An update of the use and outcomes of the new immunomodulatory agent CC-4047 (Actimid) in patients with relapsed/refractory myeloma. Blood 2003, 102 (11, Part 1): Abst 829.
164. Hasselbalch, H.C., Bjerrum, O.W., Jensen, B.A., Hansen, P.B., Birgens, H. STI57I (Gleevec) Therapy in idiopathic and post polycythemic myelofibrosis. Blood 2002, 100 (11, Part 2): Abst 4930.
165. Iwamoto, Y. A randomised, multicentre trial of biphasic insulin aspart versus biphasic human insulin in type 2 diabetes. 18th Int Diabetes Fed Congr (Aug 24, 2003, Paris) 2003: Abst 780.
166. Gisslinger, H., Gisslinger, B., Kees, M. et al. Imatinib mesylate in chronic idiopathic myelofibrosis, a phase II trial. Blood 2002, 100 (11, Part 1): Abst 3161.
167. Ben-Menachem, E. NSI209: A neuroprotective AMPA antagonist with pronounced anticonvulsive and anti-epileptogenic effect in preclinical models. Epilepsia 2003, 44 (Suppl. 9): Abst 2.239.
168. Krusz, J.C. Valdecoxib treats moderate migraines and headaches. 7th Congr Eur Fed Neurol Soc (Aug 30, 2003, Helsinki) 2003: Abst 328.
169. Krystal, A.D., Walsh, J.K., Laska, E. et al. Sustained efficacy of eszopiclone over 6 months of nightly treatment: Results of a randomized, doable-blind, placebo-controlled study in adults with chronic insomnia. Sleep 2003, 26(7): 793.
170. Niederhofer, H., Staffen, W., Mair, A., Pittschieler, K. Melatonin facilitates sleep in individuals with mental retardation and insomnia. J Autism Dev Disord 2003, 33(4): 469.
171. Mathew, N., Schoenen, J., Winner, P., Sikes, C., Muirhead, N. Eletriptan 40 mg vs sumatriptan 100 mg: Results of a multicenter, randomized, placebo-controlled trial. Headache 2003, 43(5): Abst F30.
172. Weis, K.A. Cost effectiveness of eletriptan vs. sumatriptan in the treatment of migraine. 7th Congr Eur Fed Neurol Soc (Aug 30, 2003, Helsinki) 2003: Abst 348.
173. Steiner, T.J. et al. Comparative efficacy of eletriptan and zolmitriptan in the acute treatment of migraine. Cephalalgia 2003, 23(10): 942.
174. Rasmussen, S. et al. Efficacy of eletriptan in patients who were dissatisfied with prior medications for acute treatment of migraine. 7th Congr Eur Fed Neurol Soc (Aug 30, 2003, Helsinki) 2003: Abst 647.
175. McCleane, G., Koch, B., Rauschkolb, C. Does SPM 927 have an analgesic effect in human neuropathic pain? An open label study. Neurosci Lett 2003, 352(2): 117.
176. Strupp, M., Schuler, O., Kraftczyk, S. et al. Treatment of downbeat nystagmus with 3,4-diaminopyridine: A placebo-controlled study. Am J Ophthalmol 2003, 136(5): 971.
177. Ault, P., Kantarjian, H., O'Brien, S., Garcia-Manero, G., Rios, M.B., Cortes, J.E. Use of darbepoetin alfa for the treatment of anemia occurring during imatinib therapy for CML: Preliminary evidence of safety and efficacy. Proc Am Soc Clin Oncol 2003, 22: Abst 2467.
178. Keck, P.E. Jr., Marcus, R., Tourkodimitirs, S. et al. A placebo-controlled, double-blind study of the efficacy and safety of ciripiprazole in patients with acute bipolar mania. Am J Psychiatry 2003, 160(9): 1651.
179. Auquier, P., Robitail, S., Llorea, P.-M., Rive, B. Comparison of escitalopram and citalopram efficacy: A meta-analysis. Int J Psychiatry Clin Pract 2003, 7(4): 259.
180. Grunze, H., Langosh, J., Born, C., Shaub, G., Walden, J. Levetiracetam in the treatment of acute mania: An open add-on study with an on-off-on design. J Clin Psychiatry 2003, 64(7): 781.
181. Delgado, P.L., Mallinckrodt, C.H., Wang, F. et al. Comparison of sexual functioning in patients receiving duloxetine or paroxetine: Acute- and long-term. 4th Int Forum Mood Anxiety Disord (Nov 19, 2003, Monte-Carlo) 2003: Abst P06.
182. Detke, M., Gilaberte, I., Perahia, D.G. et al. Duloxetine vs placebo in the prevention of relapse of major depressive disorder. 4th Int Forum Mood Anxiety Disord (Nov 19, 2003, Monte-Carlo) 2003: Abst P07.
183. Feiger, A.D., heiser, J.F., Shrivastava, R.K. et al., Gepirone extended-release: New evidence for efficacy in the treatment of major depressive disorder. J Clin Psychiatry 2003, 64(3): 243.
184. Raskin, J., Goldstein, D.J., Mallinckrodt, C.H., Ferguson, M.B. Duloxetine in the long-term treatment of major depressive disorder. J Clin Psychiatry 2003, 64(10): 1237.
185. Thase, M.E., Lu, Y., Joliat, M.J., Treuer, T., Detke, M.J. Remission in placebo-controlled trials of duloxetine with an SSRI comparator. 4th Int Forum Mood Anxiety Disord (Nov 19, 2003, Monte-Carlo) 2003: Abst P32.
186. Kane, J.M., Carson, W.H., Saha, A.R. et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2002, 63(9): 763.
187. Falissard, B., Lothgren, M., Perahia, D., Garcia-Cebrian, A. Meta-analyses of duloxetine in the treatment of MDD. 4th Int Forum Mood Anxiety Disord (Nov 19, 2003, Monte-Carlo) 2003: Abst P13.
188. Rein, W., Arvanitis, L. Antipsychotic effect of four different compounds - results of the metatrial. Eur Neuropsychopharmacol 2003, 13 (Suppl. 4): S95.
189. Casey, D.E., Carson, W.H., Saba, A.R. et al. Switching patients to aripiprazole from other antipsychotic agents: A multicenter randomized study. Psychopharmacology 2003, 166(4): 391.
190. Jacobs, A. et al. Evaluation of the efficacy and safety of levetiracetam in patients with refractory partial epilepsy. 7th Congr Eur Fed Neurol Soc (Aug 30, 2003, Helsinki) 2003: Abst 69.
191. Patterson, B.E., Mitchell, M.I., Bedding, A.W. et al. Tadalafil and inducers, inhibitors, and substrates of cytochrome P450 isoenzyme 3A4 (CYP3A4). Int J Impot Res 2003, 15 (Suppl. 5): Abst 26.
192. Brock, G., Stief, G., Porst, H., Saenz De Tejada, I., Ulbrich, E. Sustained efficacy and tolerability of vardenafil (Levitra®) over 2 y in men with erectile dysfunction. Int J Impot Res 2003, 15 (Suppl. 5): Abst 32.
193. Shabsigh, R., Eardley, I., Whitaker, S., Denne, J., Ahuja, S. Time distribution of sexual intercourse attempts after taking tadalafil or placebo. Int J Impot Res 2003, 15 (Suppl. 5): Abst 36.
194. Carson, C., Porst, H., Kaufman, J.M., Ahuja, S., Wang, C. Tadalafil is effective in treating mild to severe erectile dysfunction. Int J Impot Res 2003, 15 (Suppl. 5): Abst 28.
195. Kaufman, J.M., Ahn, T.-Y., Schulman, C.C., Shen, W. Tadalafil allows for early succes and maintenance of successful intercourse in men with erectile dysfunction. Int J Impot Res 2003, 15 (Suppl. 5): Abst 35.
196. Carrier, S., Shin, J., Anglin, G., Iglesias, J. Phase III canadian clinical experience with tadalafil (Cialis™). Int J Impot Res 2003, 15 (Suppl. 5): Abst 24.
197. Burger, N.Z., Protas, E., Davis, B., Buster, J.E., Carson, S.A., Casson, P.R. Effect of physiologic oral dehydroepiandrosterone (DHEA) replacement on exercise tolerance in postmenopausal women. Fertil Steril 2003, 80 (Suppl. 3): Abst P-362.
198. Tamura, S., Ueki, K., Kuroiwa, T. et al. Comparison of efficacy between oral calcitriol and intravenous 22-oxacalcitriol therapies in chronic hemodialysis patients. Nephrol Dial Transplant 2003, 18 (Suppl. 4): Abst M458.
199. Kavoussi, R. Pregabalin compared with other anxiolytics in GAD. 4th Int Forum Mood Anxiety Disord (Nov 19, 2003, Monte-Carlo) 2003: Abst S0601.
200. Di Marco, F., Santus, P., Boveri, B., Verga, M., Matera, M.G. Onset of action of tiotropium (TIO) + formoterol (FOR) in patients with stable COPD. Eur Respir J 2003, 22 (Suppl. 45): Abst P1845.
201. Donohue, J.F. et al. Tolerance to bronchodilating effects of salmeterot in COPD. Respir Med 2003, 97(9): 1014.
202. Stojkovic-Andjekovic, A.K., Savic, D.P., Protrka, O.S., Obradovic, S.D., Knezevic, J.S. Effect of desloratadine on patients suffer from allergic rhinitis and bronchial hyperreactivity. Eur Respir J 2003, 22 (Suppl. 45): Abst P893.
203. Young, J., Goldstein, I., Fischer, J., Segerson, T., Taylor, T. Vardenafil (Levitra) improved satisfaction with erectile hardness, orgasmic function, and sexual experience in men with diabetes with erectile dysfunction. Diabetes 2003, 52 (Suppl. 1): Abst 68-OR.
204. Langley, R.G.B. The efficacy and safety of efalizumab for patients with moderate to severe plaque psoriasis. J Eur Acad Dermatol Venereol 2003, 17(8): Abst P27-40.
205. Kapp, A., Pichler, W.J. Levocetirizine is a potent treatment in patients suffering from chronic idiopathic urticaria: A randomised double blind placebo controlled parallel multicentric study. 22nd Congr Eur Acad Allergol Clin Immunol (June 7, 2003, Paris) 2003: Abst 268.
206. Papp, K., Bissonnette, R. Patients report high level of satisfaction with efalizumab therapy. J Eur Acad Dermatol Venereol 2003, 17(8): Abst P27-39.
207. Holck, D.E.E. et al. Comparison of high-dose botulinum toxin Type B to botulinum toxin Type A in the ameliorationof lateral canthal wrinkles. Annu Meet Am Acad Ophthalmol (Nov 15, 2003, Anaheim) 2003: Abst PA020.
208. Saint-Martin, F., Aubier, M., Pradalier, A. Desloratadine improves quality of life questionnaire scores in patients with seasonal allergic rhinitis. 22nd Congr Eur Acad Allergol Clin Immunol (June 7, 2003, Paris) 2003: Abst 237.
209. Meurer, M. A year's experience in practical, long-term management of atopic eczema with Elidel. J Eur Acad Dermatol Venereol 2003, 17(8): Abst SAT3-3.
210. Hesketh, P.J., Grunberg, S.M., Gralla, R.J. et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: A multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin - The Aprepitant Protocol 052 Study Group. J Clin Oncol 2003, 21(22): 4112.
211. Morris, E.C., Rebello, P., Thomson, K.J. et al. Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: Relevance for early adoptive immunotherapy and infectious complications. Blood 2003, 102(1): 404.
212. Kahan, B.D., Karlix, J.L., Ferguson, R.M. et al. Pharmacodynamics, pharmacokinetics, and safety of muhiple doses of FTY720 in stable renal transplant patients: A multicenter, randomized, placebo-controlled, phase I study. Transplantation 2003, 76(7): 1079.
213. Danziger-Isakov, L.A., Faro, A., Sweet, S. et al. Variability in standard care for cytomegalovirus prevention and detection in pediatric lung transplantation: Survey of eight lung transplant programs. Pediatr Transplant 2003, 7(6): 469.
214. Maes, B.D. et al. Influence of SDZ RAD vs. MMF on gastric emptying in renal transplant recipients. Clin Transplant 2003, 17(3): 171.
215. McCance-Katz, E.F. et al. The protease inhibitor lopinavir-ritonavir may produce opiate withdrawal in methadone-maintained patients. Clin Infect Dis 2003, 37(4): 476.
216. Delgado-Aros, S., Chial, H.J., Cremonini, F. et al. Effects of asimadoline, a kappa-opioid agonist, on satiation and postprandial symptoms in health. Aliment Pharmacol Ther 2003, 18(5): 507.
217. Mistry, G., Herman, G., Xi, L. et al. Single i.v. doses of ertapenem are not associated with clinically significant QTc prolongation. Clin Microbiol Infect 2003, 9 (Suppl. 1): Abst P469.
218. Wajcberg, E., Myiazaki, Y., Triplitt, C., Cersosimo, E., DeFronzo, R.A. Dose response effect of a single dose of orally administered hexyl-insulin monoconjugate (HIM2) in healthy nondiabetic subjects. 18th Int Diabetes Fed Congr (Aug 24, 2003, Paris) 2003: Abst 805.
219. Rave, K., Nosek, L., Heinemann, L., Jacobsen, L. Insulin detemir and NPH insulin: Comparison of pharmacokinetic and pharmacodynamic properties in Japanese and Caucasian volunteers. Diabetes 2003, 52 (Suppl. 1): Abst 1963-PO.
220. Mather, K., Lteif, A., Steinberg, H., Baron, A. Endothelin antagonism does not alter metabolic response to insulin in humans. Diabetes 2003, 52 (Suppl. 1): Abst 1431-P.
221. Nickelsen, T., Samel, A., Vejvoda, M., Wenzel, J., Smith, B., Gerzer, R. Chronobiotic effects of the melatonin agonist LY 156735 following a simulated 9h time shift: Results of a placebo-controlled trial. Chronobiol Int 2002, 19(5): 915.
222. Fung, T.T., Manson, J.E., Solomon, C.G., Liu, S., Willett, W.C., Hu, F.B, The association between magnesium intake and fasting insulin concentration in healthy middle-aged women. J Am Coll Nutr 2003, 22(6): 533.
223. von Eckardstein, S., Noe, G., Brache, V. et al. A clinical trial of 7Α-methyl-19-nortestosterone implants for possible use as a long-acting contraceptive for men. J Clin Endocrinol Metab 2003, 88(11): 5232.
224. Majumdar, A.K., McCrea, J.B., Panebianco, D.L. et al. Effects of aprepitant on cytochrome P450 3A4 activiTy using midazolam as a probe. Clin Pharmacol Ther 2003, 74(2): 150.
225. Shiomi, M., Funaki, T. Pharmacokinetic/pharmacodynamic model analysis of pegylated interferon α-2α in healthy subjects. Jpn J Clin Pharmacol Ther 2003, 34(4): 177.
226. Liles, W.C., Broxmeyer, H.E., Rodger, E. et al. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood 2003, 102(8): 2728.
227. Petrig, C. et al. Effect of tegaserod on faecal water and electrolyte secretion in male female subjects. Gut 2002, 51 (Suppl. 3): Abst WED-G-322.
228. Petrig, C. et al. Effect of tegaserod on gastrointestinal transit in male and female subjects. Gut 2002, 51 (Suppl. 3): Abst MON-G-512.
229. Sesoko, S., Umemura, K., Nakashima, M. Pharmacokinetics (PK), safety, and tolerability of tigecycline (GAR-936) in healthy Japanese males. 42nd Intersci Conf Antimicrob Agents Chemother (Sept 27, 2002, San Diego) 2002: Abst A-1403.